Stock Taper Net Operating Revenues: $5.4 billion
Consolidated Adjusted EBITDA: $1.16 billion, representing a margin of 21.6%
USPI Adjusted EBITDA: $484 million, with a margin of 36.7%
Hospital Segment Adjusted EBITDA: $678 million, with a margin of 16.7%
Same-Facility Revenue Growth (USPI): 5.3%
Adjusted Free Cash Flow: $978 million
Share Repurchases: 1.35 million shares for $318 million
Cash on Hand: $2.97 billion with no debt under the line of credit
USPI Performance: Strong start with significant growth in same-store volume for total joint replacements and a robust pipeline for acquisitions, investing $125 million to acquire 7 ASCs.
Hospital Segment: Focused on disciplined expense management and growth initiatives, maintaining margins despite headwinds from payer mix and exchange enrollment declines.
Technology Investments: Continued investments in AI and automation to improve operational efficiencies and clinical throughput.
Operational Resilience: Successfully managed impacts from winter storms and vendor cyber attacks, rescheduling procedures to mitigate disruptions.
Full Year 2026 Guidance: Reaffirmed with an expected adjusted EBITDA growth of 10% at the midpoint, excluding non-recurring items and impacts from the expiration of premium tax credits.
Q2 2026 Expectations: Anticipated consolidated adjusted EBITDA to be 24%-25% of the full year guidance.
Adjusted Free Cash Flow Projection: Expected to range between $1.6 billion to $1.83 billion, including $150 million in tax payments related to the Conifer transaction.
Payer Mix Issues: Notable declines in exchange coverage, with same-store exchange admissions down 10% year-over-year, raising concerns about future volumes.
Uncompensated Care: Increase in uncompensated care linked to the expiration of exchange subsidies, though not significantly impacting overall hospital performance yet.
Operational Headwinds: Impact from weather-related disruptions and a decline in respiratory admissions, which traditionally contribute to higher volumes and margins.
Regulatory Risks: Ongoing uncertainty regarding Medicaid trends and potential impacts from upcoming outpatient rules from CMS.
Payer Denials: Management acknowledged high levels of payer disputes and denials, but noted no significant changes in trends compared to previous quarters.
Market Strategies: Discussion on successful strategies in various markets, emphasizing a focus on high-acuity service lines and operational efficiencies.
Length of Stay Management: Continued improvements in length of stay metrics despite a focus on higher acuity services, indicating effective capacity management.
Regulatory Outlook: Anticipation of regulatory changes, particularly regarding outpatient care reimbursement, with a focus on maintaining operational efficiency and value delivery. Overall, Tenet Healthcare reported a strong start to 2026 with solid financial performance, strategic investments, and a focus on operational efficiency, while also navigating challenges related to payer mix and regulatory uncertainties.
SOURCE: Q1 2026 EARNINGS CALL TRANSCRIPT